Brian Burke, Director, Business Development, Horizon Diagnostics presenting at World CDx in London on 16th March:- Controlling Chaos in Oncology Testing: • Oncology testing is critical in the fight against cancer and the ever increasing number of biomarkers and testing modalities continue to drive complexity • How do we continue to successfully develop drugs and supporting diagnostics while maintaining quality outcomes for patients?
The Angle video from the recent presentation is up on the Shares Mag web site: http://www.sharesmagazine.co.uk/videos?vid=63338
AN doing a presentation at the Innovators & Investors Forum on Tuesday 2nd February 2016 in London. http://www.sharesmagazine.co.uk/events/event/iif2016/
I think there's a bit of a fight going on between the bears and the bulls. People are selling but the price isn’t falling, so I think there must be a big buyer in the background. For what it is worth, the charts are telling me we should see some upward movement in the next week of two. Time will tell …..
There was some talk about this at the AGM. What came over to me at the meeting was that the board have a very clear strategy of how they are going to grow the business and they are very focussed on following that strategy. Realistically though, they are very aware that the company could well be the target of a takeover bid at some stage. Whether or not that happens is to some extent outside of their control and they will have to react accordingly when that happens.
http://www.genengnews.com/gen-articles/enabling-a-paradigm-shift-in-precision-medicine/5584/
Argyle A quick blood test would perhaps be ideal but they cannot do that without first of all doing the trial and getting the trial data to prove the efficacy and accuracy of the process. Angle hope to have a 2nd trail – probably around prostate cancer – following on behind the ovarian trial.
Particularly like …. ”Newland expects Parsortix to be in clinical use in Europe before the end of 2016 for patients that potentially have ovarian cancer. Even better, there is already Medicare reimbursement coverage in place for ovarian cancer tests, which might ease the technology's introduction in the United States.”
http://www.businessweekly.co.uk/news/biomedtech/california-deal-triggers-potential-horizon-gold-rush
Wisheyed, I followed this link. ...... http://subscribe.agorafinancial.co.uk/X976R721?email=test@example.como His first company is definitely Angle and I’m pretty sure the second is Qiagen. Haven’t a clue who the 3rd company is, though it will be one of the big boys so probably won't see a very large percentage change in SP.
SS. Not sure about the no more dilution bit. They raised money earlier in the year to cover the costs of the extended ovarian trial that’s being run with Vienna. If they can, I’m sure that they would want to do additional trials – perhaps around prostate cancer with Barts. If so then I would guess they may pass the hat around again to cover the costs of the additional trial(s).
http://brrmedia.co.uk/event/139298/kieron-harbinson-group-finance-director
I managed to get along to the event last night. Not a great deal new came out in the presentation that hasn’t been said before – I think it will be uploaded in the fullness of time. A couple of points that I did pick up from the presentation and from conversation later in the bar: • Further patent confirmations are to be expected covering other countries. • Andersons are very pleased with the system – so hopefully we’ll get a firm recommendation from them. • Now they are moving into the “Translational Research” stage – i.e. how to commercialise the product. We know that it can harvest CTCs ... so the question is how to incorporate that into a clinical procedure. Note the grant of £5m to Christie’s in Manchester that was awarded a few days ago could be used to further this. • Five of the 9 KOLs have so far reported their initial findings and thoughts on Parsortix. They expect the other 4 to report over the next 6 months. • They expect the first Research sales in Q4 this year. • The build of sales into the clinical world will only come to fruition when the KOLs come out with recommendations on how the technology can be commercialised i.e. the KOLs need to come out with a recommended ways of working that uses Parsortix to solve a clinical problem. This is why the Vienna trial is so important – it’s the first. The problem they are looking into is how to triage ladies with a growth in their ovary which might or might not be cancer – there is no reliable way of determining this at the moment. The use of Parsortix provides a solution to that. What the trial is doing is basically showing that the proposed solution is statistically sound. Once that is complete (estimated Q4, 2016) then the solution can be rolled out to the clinical world. Until the KOL (i.e. Vienna in this case) state that the technology and statistics are valid, there won’t be any traction in selling Parsortix into the clinical ovarian cancer world. So, with respect to the platform FDA ruling. Yes, we want it as soon as possible, but that in itself will have little impact on clinical sales. Clinical sales hinge on the KOLs.
16 months – ouch. Anything behind that or just a guess? We’re totally in FDA’s hands and can only wait and be patient. About 94% of FDA 510(k) submissions get cleared within 12 months. The exam question that Angle have set for them is different from the norm so there was no way that we were ever going to get a response in 12 months. Another 16 months though, would mean that they will have taken about 30 months in total. I was kind of hoping for a decision before the end of the year.